Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2003

View Archived Issues

Beneficial effects described for NN-2211 in the treatment of type 2 diabetes

Novel 5-HT1 receptor ligands discovered by GSK researchers

AstraZeneca presents dual CCR3 modulators/histamine H1 antagonists

New 5-HT6 receptor ligands designed by Akzo Nobel scientists

Two series of carbamate-based analgesic agents newly developed at Gruenenthal

AxyS presents novel factor VIIa/factor Xa inhibitors

Novel Jak kinase inhibitors for use in inflammation and cancer

ArQule completes Cyclis acquisition

Requip sNDA for restless legs syndrome filed

Aventis and Regeneron enter global agreement for VEGF Trap

Takeda acquires Japanese rights to antiobesity drug candidate ATL-962

Private equity financing to advance development of Panvac-VF and Prostvac-VF

NIAID grant supports development of oral smallpox drug at Chimerix

Phase I trial evaluates Psoraxine for psoriasis

Antisoma acquires Cytogen's R-1549 royalty rights

Clofarabine granted fast track status for pediatric leukemia

Improved glycemic control associated with exenatide in diabetes

SBIR grant supports BioSante's oral insulin development efforts

Rexin-G designated an orphan drug for pancreatic cancer

Phase I/II trial approved to evaluate Collidem in colorectal cancer

StaphVAX immunogenicity trial successfully completed

Positive endoscopy results for NCX-4016

NDA filed for cinacalcet hydrochloride

EntreMed grants Oxford BioMedica gene rights for ophthalmic applications

Abilify sNDA approved for maintaining stability in patients with schizophrenia

Taisho discusses design and SAR of group II mGluR antagonists at ACS meeting

Inhibitors of procollagen C-endopeptidase synthesized and evaluated as potential antifibrotic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.